Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21152759 | 0.82 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP2C19ELANEHPGD | |
| SCHEMBL21788003 | 0.82 | ALDH1A1 (0.41) | CYP3A4CYP2C9CYP2C19ELANEHPGD | |
| SCHEMBL24923945 | 0.76 | ALDH1A1 (0.50) | ELANEHPGDALDH1A1LMNANPC1 | |
| SCHEMBL22273593 | 0.74 | POLB (0.42) | CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL11063207 | 0.73 | ALDH1A1 (0.50) | ALDH1A1LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27277585 | 0.72 | CYP2C19 (0.47) | CYP3A4CYP2C9CYP2C19ALDH1A1NPC1 | |
| SCHEMBL24478549 | 0.72 | SLC1A2 (0.41) | CYP3A4CYP2C9CYP2C19ELANEHPGD | |
| SCHEMBL24534624 | 0.72 | ALDH1A1 (0.49) | ALDH1A1KDM4ELMNANPC1RAB9A | |
| SCHEMBL10946417 | 0.72 | ALDH1A1 (0.49) | ALDH1A1KDM4ELMNANPC1RAB9A | |
| SCHEMBL25948326 | 0.72 | ALDH1A1 (0.49) | ALDH1A1KDM4ELMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | SDCBP, DDOST, KRTCAP2 | CYP3A4 3209/4885CYP2C9 3715/4885CYP2C19 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.